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Abstract
The central region of smooth muscle caldesmon is predicted to form ?-helices on the basis of its
primary structure. We have isolated a fragment (CT54) that contains this region. The hydrodynamic
properties and the electron microscopic images suggest that CT54 is an elongated (35 nm),
monomeric molecule. The circular dichroic spectrum yields an overall ?-helical content of 55–58%.
These results are consistent with the model that the middle portion of CT54 forms a long stretch of
single-stranded ?-helix. Such a structure, if it in fact exists, is thought to be stabilized by numerous
salt bridges between charged residues at positions i and i+4. The structural characteristics of this
fragment not only represent an unusual protein configuration but also provide information about the
functional role of caldesmon in smooth muscle contraction.
Both smooth muscle and non-muscle cells contain a major heat-stable, actin-binding protein,
caldesmon (1, for reviews, see Refs. 2,3). Although the exact physiological role of caldesmon
remains uncertain, its inhibition of actomyosin-activated ATP hydrolysis in vitro (4–7), its
ability to respond to changes of the calcium concentration via interactions with calmodulin
(4–6), and its binding to myosin (8,9) have prompted much speculation that this thin filament-
associated protein may be involved in some auxiliary mechanism for regulation (10–12). On
the basis of its predicted secondary structure (13,14) and recent electron microscopic images
(15), the molecule of smooth muscle caldesmon can be roughly divided into three parts: the
N-terminal portion (residues 1–249),1 the middle portion (residues 250–396), and the C-
terminal portion (residues 397–756). The non-muscle form, however, has only the two terminal
portions, with the middle part found in smooth muscle caldesmon missing (3,16–18). The
muscle form of caldesmon is better characterized than the non-muscle isoform both structurally
and functionally. The C-terminal portion contains most of the functional domains, viz. regions
for actin binding (19–22), calmodulin binding (19,20,22–25), and ATPase inhibition (19,23);
the N-terminal portion contains the myosin-binding site (26–28) and a putative, secondary,
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1To this date, there are two non-identical cDNA clones from the chicken gizzard library that have been identified and sequenced. One
isoform (771 residues, Ref. 14) is 15 residues longer than the other (756 residues, Ref. 13). The difference (AAEERERAKAEEERK)
occurs in the middle part of the molecule, where the longer isoform contains an extra repeating unit (see “Results and Discussion”). The
degree of precision in our amino acid composition analysis results (Table I) does not allow us to differentiate between the two isoforms,
although the molecular weight is more consistent with the smaller isoform. For the sake of discussion, we assume our CT54 is from the
756-residue isoform and use the numbering system of this smaller form unless indicated otherwise.
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calmodulin-binding site (25,29). No known function has yet been assigned to the middle
portion, although the amino acid sequence suggests that it has a tendency to form ?-helical
structures (13,14). Here we report the isolation of a fragment (CT54)2 that has an apparent
molecular weight from sodium dodecyl sulfate-gel electrophoresis of 54,000 and contains the
middle part of the smooth muscle caldesmon molecule. We present evidence for the existence
of a long ?-helical stretch in this fragment. The unusual length and stability of this rod-like
structure may serve as a spacer between the myosin-binding site and the actin-binding site.
MATERIALS AND METHODS
Purification of Caldesmon and CT54
Turkey gizzard caldesmon was purified as previously described (30). Purified caldesmon (5
mg/ml) in 0.1 m NaCl, 10 mm imidazole, pH 7.0, 1 mm dithiothreitol (buffer A) was cleaved
with ?-chymotrypsin (Worthington) at 1:700 ratio (chymotrypsin to caldesmon, by weight) at
25 °C for 5 min. After termination of the reaction with phenylmethanesulfonyl fluoride, the
mixture was loaded onto a 2.5 × 20-cm column of Affi-Gel Blue (100–200 mesh, Bio-Rad)
equilibrated with the same buffer. The crude CT54, which did not cosediment with F-actin,
was eluted with 250 mm NaCl, 10 mm Tris-HCl, pH 8.0, 1 mm dithiothreitol, and was further
purified on an ACA 54 column (1.5 × 90-cm, Spectrum) equilibrated with buffer A. After
concentration on an Amicon Filtration apparatus using a YM-2 membrane, the sample was
dialyzed against 50 mm NaCl, 10 mm Tris-MES, pH 7.0. The sample was then
chromatographed on a Waters HPLC using a Pharmacia LKB Biotechnology Inc. Mono Q
column with an exponential gradient to 500 mm NaCl. The major peak was concentrated and
chromatographed on the same column using a linear gradient on NaCl from 185 to 500 mm
(Fig. 1, A and B).
Ultracentrifugation Studies
Sedimentation equilibrium runs were performed as described previously (31). CT54 (0.5 mg/
ml) was centrifuged at 20,000 rpm for 72 h. A value of 0.723 cm3/g for the partial specific
volume of CT54 at 4 °C was calculated from the amino acid composition (Table I). A value
of 0.612 g of H2O/g of protein for the hydration was calculated using the values for the
individual amino acids from Kuntz and Kauzman (32). Sedimentation velocity runs were
carried out as described previously at 20 °C (31).
Circular Dichroism Measurements
CD spectra were measured in a 1-cm path length cell on an Aviv Associates (Lakewood, NJ)
model 60 DS spectropolarimeter containing a Hewlett-Packard 89100A temperature controller.
CT54 spectra were corrected by subtracting buffer spectra, and the observed ellipticity was
converted to mean residue weight ellipticity, [?] (degree-cm2/dmol). The helical contents were
calculated from [?]208 nm or by curve fitting to basis spectra according to Greenfield and
Fasman (33). Temperature-dependent CD measurements were carried out at 1.0 °C intervals
as described previously (34).
Determination of Protein Concentration
The concentration of CT54 was determined by three independent methods: (i) Lowry assay
using rabbit skeletal muscle tropomyosin as a standard (35); (ii) amino acid composition
analysis (see below for details); and (iii) refractive index measurements by ultracentrifugation
(see Ref. 31 for details). All three methods yielded values which agreed within a standard
2The abbreviations used are: CT54, the chymotryptic fragment of caldesmon having an apparent molecular weight of 54,000; MES, 2-
(N-morpholino)ethanesulfonic acid; HPLC, high performance liquid chromatography.
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deviation of 3–5%. Concentrations estimated on the basis of the molar extinction coefficient
of 5600 at 280 nm for tryptophan (36) agree reasonably well with values obtained from the
other three methods.
Electron Microscopic Studies
CT54 was examined by the minimum angle vertical rotary shadowing technique (37) on a
Philips EM 300 electron microscope at 60 kV. Other experimental details were as previously
described (15).
Amino Acid Analysis
N-terminal amino acid sequence analyses were performed on an Applied Biosystems
Sequencer (model 477A) with an on-line phenylthiohydantion analyzer (model 120A). To
determine the amino acid composition, the fragment was hydrolyzed in 6 m HCl for 20 h at
110 °C under vacuum, and the analyses were performed on a Beckman High Performance
Amino Acid Analyzer (model 7300).
RESULTS AND DISCUSSION
The 54-kDa caldesmon fragment (CT54) exhibits remarkable resistance to chymotryptic
cleavage (Fig. 1C). This fragment, purified by high performance liquid chromatography after
digestion with chymotrypsin (Fig. 1A and B), does not bind to actin, although it can be retained
on a myosin-Sepharose column under low salt (35 mm) conditions.3 CT54 migrates on
polyacrylamide gel electrophoresis in the presence of NaDodSO4 with an apparent molecular
weight of 54,000, although the actual molecular weight is about 33,000 on the basis of
sedimentation equilibrium experiments (Fig. 2). Such a discrepancy between the apparent and
true molecular weights has also been reported for the parent molecule (31) and was attributed
to its poor ability to bind the detergent owing to a high content of acidic residues (38,39). The
amino acid composition analysis of CT54 (Table I) shows 40% Glx + Asx, consistent with a
high acidic residue content. N-terminal sequence analysis reveals some heterogeneity in this
CT54 preparation: the main component (>75%) begins at Gln166, resulting from cleavages at
Tyr165, whereas the minor component (<25%) begins at Arg171, resulting from cleavages at
Trp170.
The results of our amino acid sequence and composition analyses indicate that CT54 is a 285-
residue peptide extending from Gln166 to Trp450, with a calculated molecular weight of 33,060,
consistent with the hydrodynamic measurements (see above). The fact that the majority of the
fragment contains an internal tryptophan residue (Trp170) suggests that this residue is situated
in a somewhat protected environment. There are 10 Val, 10 Leu, and 1 Ile in CT54; these
residues, normally susceptible to chymotrptic cleavages, must also be protected in order to
account for their insensitivity toward the enzyme.
Thus, CT54 covers part of the N-terminal portion and the entire middle portion of caldesmon
and amounts to about one-third of the whole molecule. Notably, this central region contains at
least nine repeats of a 12-residue unit, KAEEEK(or R)KAAEEK (Fig. 3) and has been predicted
by a number of secondary structure algorithms to have a high tendency to form ?-helical
structures (13,14). In particular, the 147 residues between 250–396 are predicted to be in an
uninterrupted string of ?-helical structure with little or no tendency to form ?-sheet or random
coil (Fig. 4). Analysis of the circular dichroism spectrum of CT54 (Fig. 5A) gives 55 ± 2% ?-
helical content from the ellipticity at 208 nm, and 58 ± 2% ?-helical content with the remainder
3While CT54 may bind to myosin, the major portion of the myosin-binding region is located in the N-terminal chymotryptic fragment
of caldesmon.
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being random coil from curve fitting to basis spectra (33). This indicates that about 160 residues
of CT54 are in an ?-helical structure. It is interesting to note that non-muscle (liver) caldesmon
lacks the central repeating region, 232 amino acid residues from Val200 being deleted, and has
a lower helical content (Table II). The difference in the ?-helical content between the intact
muscle caldesmon (40) and the non-muscle isoform (see Table II) corresponds to ~140 ?-
helical residues in this “difference peptide.” These results are consistent with the idea that the
central repeating region in smooth muscle caldesmon is nearly 100% helical.
The ?-helical structure of CT54 is highly stable, since it is rather insensitive to changes in ionic
strength and pH and unfolds at a relatively high temperature. The CD spectrum of CT54 at 20
°C remained essentially unchanged upon varying [NaCl] from 0 to 1.0 m at pH 7, and over a
wide range of pH, from 2 to 9.5 in 50 mm NaCl (Fig. 5B). There was about a 10% drop in the
?-helical content upon further increase in pH to 11 (Fig. 5B). The extraordinary stability against
both salt concentration and pH is noteworthy, and may be attributable to the intra-helical salt
bridges (see below).
CT54 undergoes a gradual thermal unfolding upon increasing the temperature from 5 to 90 °
C at pH 7 (Fig. 5B). The ellipticity of the fragment decreases gradually up to 40 °C and then,
somewhat more steeply, to 80 °C with an overall midpoint temperature (T1/2) at about 50 °C
(Fig. 5B). While the apparent T1/2 remains unchanged at pH 9.5 and only slightly decreases at
pH 2, it is considerably lower at pH 11 (Fig. 5B). These properties are similar to those of an
80-residue, highly ?-helical (80%) fragment (CB2) of troponin T (41) and of certain synthetic
peptides (see below), which also unfold over a relatively wide temperature range. In contrast
to the much sharper thermal transitions exhibited by ?-helical coiled-coils, e.g. tropomyosin
(35) and myosin rod (42), the observed gradual decrease in ellipticity of CT54 may result from
a loss of less cooperative interactions that are responsible for maintaining the structure. This
behavior could reflect the unfolding of a highly stabilized helix, either from the ends inward,
or randomly and segmentally along the entire helix.
The CT54 fragment in solution is highly asymmetric as indicated by sedimentation velocity
experiments, which yield a sedimentation coefficient of 1.44 S and an axial ratio of 24 with
the length and diameter of 35.6 nm and 1.46 nm, respectively, assuming a simple unhydrated
prolate ellipsoid. This model should be compared to the electron microscopic results (see
below). The hydrodynamic properties of a string-of-beads model were also calculated using
the program GENTRA developed by Garcia de la Torre (43). The observed molecular weight
and sedimentation coefficient can be best modeled with a rod-shaped string of 38 beads that
has a diameter of 1.00 nm and an overall length of 38.0 nm. Other models such as dumbbell-
shaped string of beads do not yield good fits, suggesting that CT54 is a uniformly elongated
molecule with little features at both ends, consistent with the electron microscopic observations
(see below).
The molecular dimension was also studied by electron microscopic visualization of the
fragment using rotary shadowing (Fig. 6), which reveals a rod-like image, similar to, although
shorter than, the intact gizzard caldesmon (10). The thickness appears less than that of the
myosin rod and tropomyosin, confirming that CT54 is not a coiled coil. The average contour
length is about 35 nm (Fig. 6, inset), in good agreement with the unhydrated dimension
calculated from the hydrodynamic parameters. As there is no evidence for dimerization (cf.
ultracentrifugation results, see Fig. 2), the observed molecular length is that of a monomer.
This length is consistent with an extended helical stretch of 157 residues (i.e. 55% of the 285
residues of CT54) that spans a length of 24.2 nm, with additional length due to the remaining,
non-helical 128 residues. The observed length would be too long for a folded structure, an anti-
parallel hairpin, for example, since an 80-residue helix spans only 12.3 nm. It is noteworthy
that the difference in length between unhydrated muscle (31) and non-muscle (3) caldesmons,
Wang et al. Page 4
J Biol Chem. Author manuscript; available in PMC 2005 October 21.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
as determined by hydrodynamic measurements, is about 21 nm (±3 nm). This value
corresponds to a minimum length of the difference peptide (see above and Table II) that
contains the central repeating sequence of muscle caldesmon and constitutes a subdomain (232
compared to 285 residues) of CT54. This difference is consistent with the observed dimension
of CT54.
The possibility of shorter ?-helical segments interspersed with random coil or turns was also
considered. But this seems unlikely because (i) there are no apparent breaks in the central
repeating region, judging from the amino acid sequence; (ii) discontinuous helical stretches
would disrupt salt bridges and may not be energetically favored (see below); and (iii) foldings
or bends in the helical stretch would tend to further shorten the length of the repeating region,
and thus would be inconsistent with the electron microscopic and hydrodynamic observations.
We therefore propose that the middle part of CT54 (from about Lys250 to Ala396, Fig. 3) exists
as a long, continuous, single ?-helix, while the rest of the fragment is neither ?-helical nor in
?-sheet. The visability of a single helical rod under the electron microscope is quite remarkable,
and is most likely due to its abundant long side-chains.
Single helical structures have been proposed for many synthetic peptides, such as poly-l-lysine,
poly-l-glutamate, and (Lys-Glu)n copolymers. Similar structures in naturally occurring
proteins, such as troponin T (41), troponin C (44,45), calmodulin (46), and certain antifreeze
proteins (47), have also been described. The length of the helical stretch found in these proteins,
however, is considerably smaller compared to the one observed in CT54. It has been suggested
that in aqueous solution single ?-helices are stabilized by intra-helical salt bridges between
residues i and i+4 (48–52). Indeed the stability of ?-helices held by (i+4)-type salt bridges is
quite remarkable. A synthetic 17-mer, (i+4)Glu,Lys, for example, unfolds over a temperature
range of 50–60 degrees; this peptide also remains stable at both pH extremes (pH 2 and 13),
and only loses 16% of its helical content when the salt concentration is raised from 0.01 to 1.0
m (49). The (i+3)Glu,Lys peptide, on the other hand, has a much lower helical content under
the same conditions and melts at a lower temperature (49,52). There are a total of 86 Glu, 56
Lys, and 21 Arg in the sequence of CT54, most of which are able to interact with a side chain
of an opposite charge at i+4 positions (Fig. 7). The 12 residues in a basic repeating unit contain
four pairs of salt bridges between the ith and the i+4th residues, giving rise to a total of at least
36 possible pairs of charge interactions between Glu and Lys (or Arg). Such a high density of
these charge interactions may thus stabilize the long helix over a wide range of salt
concentration and pH. For reasons not well understood, Glu, as the negative charge in the salt
bridges, provides additional helical stability at pH extremes (from pH 1 to 13) when compared
to Asp (48,49,51,52). This may further explain the observation that the CD spectrum is not
sensitive to pH changes, since all negatively charged residues in the helical region of CT54 are
Glus.
It is also noteworthy that, although (i+4)Glu,Lys exhibits a higher helical content than does
the isopeptide (i+4)Lys,Glu in low salt (0.01 m NaCl), the latter is better able to maintain the
secondary structure than the former in high (1.0 m) salt concentration (see Table 1 in Ref.
52). This could be attributed to the effect of the macrodipole moment (53), which is presumably
stabilized by the formation of Glu-to-Lys salt bridges but not by the salt bridges of reversed
direction (52). Almost all of the salt bridges found in the helical region of CT54 are from Lys
(or Arg) to Glu. This may be relevant to the observed stability against the salt concentration.
In view of the recent work by Åqvist et al. (54), however, it remains unsettled whether the
helix macrodipole plays any significant role in electrostatic stabilization. Nevertheless, it is
interesting to note that in CT54 there are several clusters of negative charges in the N-terminal,
presumably non-helical, region (residues 166–240), giving a net formal charge of ?13.
Similarly, there is a net formal charge of +1 in the C-terminal non-helical region (residues 400–
450). It is possible that the helical dipole moment is already stabilized by these electrostatic
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interactions, so that it no longer relies on the directionality of the intra-helical salt bridges. The
inter-relationships between the helical stability, the terminal charges, and the direction of salt
bridges may deserve more detailed studies.
Finally, the tightly associated side chains of the charged residues may be prevented from
interacting with other residues. This idea is consistent with the observations in both
ultracentrifugation and electron microscopic studies that there is very little side-by-side or other
interactions between the fragments. All the residues involved in the intra-helical salt bridges
have long side chains (Glu and Lys); this may provide the rigidity that is needed to allow their
observation under the shadowing conditions. The regularly spaced (Fig. 7), protruding salt
bridges may also protect the hydrophobic residues against proteolysis. It is interesting to note
that there are 33 Ala residues in the central repeating region, being the only major uncharged
amino acid in the sequence. This further supports the salt bridge model, since the small methyl
group of Ala would not interfere with the interactions between the charged side chains (49).
There are several irregularities found in the central repeating sequence; the existence of these
odd residues can be readily understood once the salt bridge model is adopted. For example,
there are 3 Glus in the repeating sequence Lys-Ala-Glu-Glu-Glu-Lys (or Arg); since the middle
one in the triplet is not used in salt-bridging, it may be altered without affecting the stability
of the helix within limits. This may explain the presence of Lys349 in the seventh repeating
unit (residues 346–357, see Fig. 3). Similarly, in the eighth unit there is an 11-residue insert
after Lys372 but now the pattern is disrupted so that it ends with a Lys (Lys383), it is followed
by a 2-Glu sequence (Lys-Lys-Met-Glu-Glu-Lys) in which Met386 assumes a position in which
a Glu would otherwise be. Charge interactions between i and i+4 positions can also be found
in regions outside the repeating sequences, but they are rare. It is not clear whether these
putative salt bridges would stabilize other ?-helical structures in the two end-domains.
Smooth muscle caldesmon inhibits actin-activated ATP hydrolysis by myosin but under some
conditions it actually results in an increase in the amount of myosin associated with actin (7).
This behavior has been explained by the observation that caldesmon has two functions (8). (i)
Caldesmon can bind to actin and inhibit the binding of myosin resulting in a decreased rate of
ATP hydrolysis. (ii) Caldesmon also can bind to myosin and thereby form a bridge between
actin and myosin. The actin-binding region of caldesmon is in the C-terminal region (19–22),
while the myosin binding region is in the N-terminal region (26–28). Interestingly, the binding
of caldesmon to myosin is similar in strength to its binding to actin (55). A rod-like structure
in caldesmon described here may serve as a spacer to separate these binding domains, or to
enable the N-terminal end to reach myosin while the C-terminal end is anchored to actin. It
should be noted that the non-muscle form of caldesmon does not contain such a central region
(3,16–18), suggesting that a spacer may not be needed in the non-muscle system. Among other
differences between the muscle and non-muscle systems, non-muscle myosin is not in the form
of organized filaments, in contrast to that in the muscle system. The structural difference
between the smooth muscle and the non-muscle forms of caldesmon may, therefore, be
determined by their different functional roles.
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Fig. 1. The 54-kDa fragment of caldesmon obtained from chymotryptic digestion.
To purify CT54, the chymotrypsin digestion mixture (weight ratio of chymotrypsin to
caldesmon = 1:700; t = 10 min) was chromatographed on a Waters HPLC using a Pharmacia
Mono Q column with an exponential gradient to 500 mm NaCl (A). The major peak was
concentrated and chromatographed on the same column using a linear gradient of NaCl from
185 to 500 mm (B). C, the time course of chymotrypsin digestion of caldesmon. Lanes 1 and
10, molecular mass standards (66, 45, 36, 29, 24, and 20.4 kDa); lane 2, caldesmon alone;
lanes 3–8, caldesmon (2.6 mg/ml) treated with chymotrypsin (1:400 by weight), t = 0, 3, 6, 10,
30, 60 min, noting the transient appearance of the 40-kDa fragment and the relative stable
bands around 54 kDa; lane 9, the HPLC-purified CT54.
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Fig. 2. Determination of molecular weight of CT54 by sedimentation equilibrium measurements.
High speed equilibrium ultracentrifugation runs were performed as described previously
(31). Plot shown are the number average molecular weight (Mn, open circles), the weight
average molecular weight (Mr, closed circles), and the z average molecular weight (Mz, open
squares) versus local cell concentration.
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Fig. 3. Repeating sequence in the central region of smooth muscle caldesmon.
Shown here is the sequence in one-letter code from residues 166 to 450 with the repetitive
units aligned in the middle. The sequence in parenthesis (numbered 3? and underlined) is the
extra unit found in the longer isoform by Hayashi et al. (14). The residues in italic are variable
parts in these repeats (see text for discussion). The leading unit (numbered 0) deviates
significantly from the consensus sequence and may represent a degenerated motif. Alteration
is also seen in the eighth unit which ends with an 11-residue insert.
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Fig. 4. Secondary structures of gizzard caldesmon predicted by Chou-Fasman (56) (A) and Gibrat
et al. (57) (B) algorithms.
The latter is a newer version of the Garnier-Osguthorpe-Bobson method (58). In the first
method a string of 6 residues is considered, whereas in the second method, 17 residues are
analyzed each time. The calculated conformational indeces (in arbitrary units) for ?-helices
(solid lines), ?-sheets (broken lines), and random coils (dotted lines) are plotted. The beginning
and the end of CT54 are indicated by arrows. Note that both methods predict that the central
repeating region, residues from ~245 to ~400, has a high tendency to form ?-helices, but a low
tendency to form either ?-sheets or random coils.
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Fig. 5. Circular dichroism of CT54.
Panel A, CD spectra of CT54 in 2.5 mm potassium phosphate buffer, 0.04 mm EDTA, pH 7.6,
20 °C. Panel B, thermal unfolding measured at 222 nm of CT54 in 50 mm NaCl, 20 mm sodium
phosphate buffer at pH 7.0 (closed circles), pH 2.02 (open circles), and pH 11.45 (crosses).
At pH 9.5 the melting curve is identical to that at pH 7.0. Concentration of CT54, 0.047 mg/
ml. All measurements were carried out in a 1-cm path length cell.
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Fig. 6. Electron microscopic images of CT54.
CT54 (10–20 ?g/ml) was sprayed onto the mica surface and processed for rotary shadowing
by a platinum-rich mixture (platinum/tungsten = 3:1); bar indicates 100 nm; magnification,
×150.000. Inset, a typical histogram shows the distribution of the contour length of the images.
The observed longer images are consistent with end-to-end oligomers.
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Fig. 7. Postulated salt bridges that may be responsible for stabilizing the helical structure of CT54.
Peptide segment from Lys320 to Glu337 is plotted in a helical wheel. Salt bridges are indicated
by curved lines. Residues involved in salt bridge formation are labeled with numbers. Note
that all salt bridges are formed between residues at positions i and i+4: Lys320 to Glu324,
Arg325 to Glu329, Lys326 to Glu330, etc. Glu322 is to interact with Arg318 which is not shown.
Similar charge interactions are thought to operate in other repeating units (see Fig. 3).
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Table I
Results of amino acid composition analysis of CT54 fragment
Amino acid Observed Calculateda
% %
Ala 15.34 16.1
Asx 6.55 6.67
Glx 33.5 33.7
Gly 1.65 1.05
His <0.01 0
Ile 0.61 0.35
Lys 20.0 19.65
Leu 3.53 3.51
Met 0.76 1.05
Pro 1.99 1.75
Arg 7.56 7.37
Ser 1.87 2.1
Thr 3.08 2.46
Val 3.56 3.51
Tyr <0.01 0
Trp 0.70
a
Based on the sequence from Gln166 to Trp450 (13).
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Table II
Comparison of calculated helical content of caldesmon fragments
Protein/fragment Residues ?-Helical% Method of determination No. of residues
involved in ?-helices
Gizzard caldesmon 1–756 ~40a [?]208 nm 302
Liver caldesmon 1–524 31b [?]208 nm 162
Difference peptide 200–432 60 Calculated 140
CT54 166–450 55c [?]208 nm 157
58c Curve fittingd 165
a
Ref. 40.
b
P. Graceffa, and A. Jancso, unpublished results.
c
This work.
d
Obtained by curve fitting of the entire CD spectrum of CT54 to basis spectra (33).
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